|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| error | | | | Address:  Tel:  Email: | | | | | |
| **Mycobacterium tuberculosis sequencing report** | | | | | | | | | |
| Patient name | | |  | | Patient ID | |  | | |
| Software | | | TB-Profiler1 v{{ version }} | | Date | | {{ date }} | | |
| Sequence platform | | |  | | Sample source | |  | | |
| **Summary** | | | | | | | | | |
| Strain type | | {{ sublineage }} | | | Resistance | | | {{ drtype }} | |
| Notes: | | | | | | | | | |
| **Detail**  Resistance is reported if a resistance-associated mutation has been found. Individual mutations are listed as well as their confidence values as reported in the WHO catalogue2 | | | | | | | | | |
| **Drug** | **Mutations** | | | | | **WHO confidence** | | | **Interpretation** |
| Isoniazid | {{ isoniazid\_variants }} | | | | | {{ isoniazid\_confidence }} | | | {{ isoniazid\_interpretation }} |
| Rifampicin | {{ rifampicin\_variants }} | | | | | {{ rifampicin\_confidence }} | | | {{ rifampicin\_interpretation }} |
| Ethambutol | {{ ethambutol\_variants }} | | | | | {{ ethambutol\_confidence }} | | | {{ ethambutol\_interpretation }} |
| Pyrazinamide | {{ pyrazinamide\_variants }} | | | | | {{ pyrazinamide\_confidence }} | | | {{ pyrazinamide\_interpretation }} |
| Streptomycin | {{ streptomycin\_variants }} | | | | | {{ streptomycin\_confidence }} | | | {{ streptomycin\_interpretation }} |
| Fluoroquinolones  - Levofloxacin  - Moxifloxacin | {{ levofloxacin\_variants }}  {{ moxifloxacin\_variants }} | | | | | {{ levofloxacin\_confidence }}  {{ moxifloxacin\_confidence }} | | | {{ levofloxacin\_interpretation }}  {{ moxifloxacin\_interpretation }} |
| SLIDs  - Amikacin  - Kanamycin  - Capreomycin | {{ amikacin\_variants }}  {{ kanamycin\_variants }}  {{ capreomycin\_variants }} | | | | | {{ amikacin\_confidence }}  {{ kanamycin\_confidence }}  {{ capreomycin\_confidence }} | | | {{ amikacin\_interpretation }}  {{ kanamycin\_interpretation }}  {{ capreomycin\_interpretation }} |
| p-aminosalicylic acid | {{ para\_aminosalicylic\_acid\_variants }} | | | | | {{ para\_aminosalicylic\_acid\_confidence }} | | | {{ para\_aminosalicylic\_acid\_interpretation }} |
| Ethionamide | {{ ethionamide\_variants }} | | | | | {{ ethionamide\_confidence }} | | | {{ ethionamide\_interpretation }} |
| Cycloserine | {{ cycloserine\_variants }} | | | | | {{ cycloserine\_confidence }} | | | {{ cycloserine\_interpretation }} |
| Linezolid | {{ linezolid\_variants }} | | | | | {{ linezolid\_confidence }} | | | {{ linezolid\_interpretation }} |
| Bedaquiline | {{ bedaquiline\_variants }} | | | | | {{ bedaquiline\_confidence }} | | | {{ bedaquiline\_interpretation }} |
| Delamanid | {{ delamanid\_variants }} | | | | | {{ delamanid\_confidence }} | | | {{ delamanid\_interpretation }} |
| References:  1. Phelan, J., O’Sullivan, D.M., Machado, D. et al. Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs. Genome Med 11, 41 (2019). https://doi.org/10.1186/s13073-019-0650-x  2. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO. | | | | | | | | | |